Host immunity and vaccine development against Dengue virus

Area of Science:

• * Virology and Immunology
• * Infectious Diseases
• * Vaccine Development

Background:

• * Dengue virus (DENV) is a major global mosquito-borne viral illness, with estimates of 390 million annual infections.
• * Over half the world's population is at risk of DENV infection.
• * Current control methods are insufficient, and the only licensed vaccine, Dengvaxia, has limitations in efficacy and safety for seronegative individuals.

Purpose of the Study:

• * To analyze cellular and humoral immune responses to Dengue virus (DENV).
• * To evaluate the relationship between these immune responses and the efficacy of DENV vaccine candidates.
• * To provide insights for the development of novel DENV vaccines.

Main Methods:

• * Review of scientific literature on Dengue virus (DENV) immunology and vaccine efficacy.
• * Analysis of studies focusing on cellular and humoral immune responses.
• * Evaluation of clinical data related to DENV vaccine candidates.

Main Results:

• * Vaccine-induced cellular and humoral immune responses are critical for immunogenicity and clinical protection against Dengue virus (DENV).
• * Existing Dengue virus (DENV) vaccines may not elicit balanced immunity across all serotypes.
• * Understanding immune responses is key to improving vaccine effectiveness.

Conclusions:

• * Further research into Dengue virus (DENV) immune responses is essential for advancing vaccine development.
• * Developing vaccines that induce balanced immune responses against all DENV serotypes is a priority.
• * Feasible approaches for future Dengue virus (DENV) vaccine development are summarized.